Yasushi Horai

TL;DR: This paper evaluated the metabolic impact of farnesoid X receptor activation by administering a synthetic FXR agonist (GW4064) to mice in which obesity was induced by a high fat diet.

TL;DR: It is suggested that BABR could be useful for the management of the impaired glucose tolerance of the metabolic syndrome, since they not only lower cholesterol levels, but also reduce obesity and improve insulin resistance.

TL;DR: The data established that peroxisomal processing protease Tysnd1 is necessary to mediate the physiological functions of PTS2-containing substrates, which might cause the mild Zellweger syndrome spectrum-resembling phenotypes.

TL;DR: In obese subjects, ezetimibe reduces hepatic LXR activity by reducing hepatic oxysterols to lower hepatic oleate content, which improves steatosis and reduces oxidative stress, and this reduction improves insulin signaling in the liver.

TL;DR: Data using apoE-KO mice indicate that cholesterol and its metabolites are involved in regulating TG metabolism through a suppression of lipin-1 andlipin-2 in the liver.